2348 On Other Exchanges
2348 is not on other exchanges.

dawnrays pharmaceutical hold (2348) Snapshot

Previous Close
Day High
Day Low
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for DAWNRAYS PHARMACEUTICAL HOLD (2348)

Related News

No related news articles were found.

dawnrays pharmaceutical hold (2348) Related Businessweek News

No Related Businessweek News Found

dawnrays pharmaceutical hold (2348) Details

Dawnrays Pharmaceutical (Holdings) Limited, an investment holding company, develops, manufactures, and sells non-patented pharmaceutical medicines in Mainland China and internationally. The company operates in two segments, Intermediates and Bulk Medicines, and Finished Drugs. It offers cephalosporin antibiotics, including intermediates, bulk medicines, and powder for injections; and specific medicines comprising therapeutic areas for anti-HBV, anti-allergic, cardiovascular system, digestive system, urinary system, and endocrine system with dosage forms of tablets, capsules, and granules, as well as midbody. The company was founded in 1995 and is headquartered in Wanchai, Hong Kong. Dawnrays Pharmaceutical (Holdings) Limited is a subsidiary of Fortune United Group Limited.

902 Employees
Last Reported Date: 09/7/16
Founded in 1995

dawnrays pharmaceutical hold (2348) Top Compensated Officers

Co-Founder, Chairman, Chairman of Nomination ...
Total Annual Compensation: CNY885.0K
Co-Founder and Executive Director
Total Annual Compensation: CNY545.0K
Executive Director
Total Annual Compensation: CNY545.0K
Compensation as of Fiscal Year 2015.
dawnrays pharmaceutical hold
Dawnrays Pharmaceutical Holdings Limited To Be Deleted From Other OTC

Dawnrays Pharmaceutical Holdings Limited ordinary shares (Cayman Islands) will be deleted from Other OTC, effective September 9, 2016. The deletion was due to inactive security.

Dawnrays Pharmaceutical Holdings Ltd. Reports Unaudited Consolidated Earnings Results for the First Six Months Ended of June 30, 2016

Dawnrays Pharmaceutical Holdings Ltd. reported unaudited consolidated earnings results for the first six months ended of June 30, 2016. For the quarter, the company reported net cash flows from operating activities of RMB 182,820,000 compared to RMB 173,214,000 a year ago. Purchases of items of property, plant and equipment and construction in progress were RMB 13,752,000 compared to RMB 21,909,000 a year ago. Purchases of intangible assets were RMB 70,000 compared to RMB 130,000 a year ago.

Dawnrays Pharmaceutical Holdings Ltd. Declares Interim Dividend for the Year Ending 31 December 2016

Dawnrays Pharmaceutical Holdings Ltd. announced that the Board has resolved to declare an interim dividend of HKD 0.03 per share for the year ending 31 December 2016, approximately amounting to a total sum of HKD 24,074,000 (approximately equivalent to RMB 20,673,000). The record date for the purpose of determining shareholders' entitlement to the interim dividend is 19 September 2016. Dividend warrants will be dispatched to shareholders on or about 28 September 2016.


The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

2348 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 2348.
View Industry Companies

Industry Analysis


Industry Average

Valuation 2348 Industry Range
Price/Earnings 11.4x
Price/Sales 3.5x
Price/Book 2.1x
Price/Cash Flow 11.3x
TEV/Sales 2.6x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact DAWNRAYS PHARMACEUTICAL HOLD, please visit www.dawnrays.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.